Netherlands-based nutritional ingredient developer NutriLeads has raised an undisclosed sum in a seed round featuring DSM Venturing, the corporate venturing subsidiary of health and nutrition product supplier DSM.
Shift Invest, the venture capital fund backed by insurance company Menzis and financial services firm Rabobank, Dutch regional investment firm PPM Oost and VC firm Thuja Capital also took part in the round.
IMPP-1, NutriLeads’ primary ingredient, is derived from a traditional Chinese herbal remedy, used to help the immune system and fight infection.
NutriLeads aims to develop the ingredient, which is now sourced sustainably from specific crops, into a supplement to be included in specialist health and medical-related foods. The funding will enable the company to speed up its development and start clinical testing.
Erik Dam, chief business officer of Nutrileads, said: “The consortium of investors is carefully composed to support NutriLeads through its next development stages and it provides highly relevant and complementary expertise and networks.”